NYSE$TEVA
Teva Pharmaceutical Industries ADR · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Teva's Q1 2024 performance was driven by growth in generics and AUSTEDO, with revenues increasing by 5% in local currency terms.
Teva Pharmaceutical Industries Ltd. reported a positive start to 2024, with global revenues of $3.8 billion, reflecting a 5% increase in local currency terms compared to Q1 2023. This growth was fueled by robust performance in the generics business across all regions and continued expansion of innovative brands AUSTEDO and AJOVY. The company reaffirmed its full-year 2024 financial outlook.
- Q1 2024 revenues reached $3.8 billion, a 5% increase in local currency terms compared to Q1 2023, driven by generics and AUSTEDO.
- Generics business grew across all regions, with a 9% increase in local currency terms globally compared to Q1 2023.
- AUSTEDO sales increased by 67% in the U.S. compared to Q1 2023, reaffirming the 2024 revenue outlook of approximately $1.5 billion.
- AJOVY revenues increased to $113 million in Q1 2024, up 18% from Q1 2023.
Headline financials
Revenue & EPS history
Teva · Revenue · Quarterly
$3.82B
Revenue by segment
Teva · $1.85B total across 3 segments · Q3 2023
- Europe$1.15B+7.2%62.0%
- International Markets$485M+2.1%26.2%
- Other Activities$217M—11.7%
Forward guidance
Teva reaffirmed its full year 2024 business outlook.
Tailwinds
- Revenues of $15.7 - $16.3 billion
- Adjusted EBITDA of $4.5 - $5.0 billion
- Non-GAAP diluted EPS of $2.20 - $2.50
- Free cash flow of $1.7 - $2.0 billion
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2024
+0.3%
Avg return
Earnings day
+1.6%
Avg return
5 days after
+0.7%
Avg return
30 days after
51%
38 / 74 earnings
Positive
+27.1%
Q2 2022
Best reaction
-34.1%
Q2 2017
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.1% | +11.9% | +11.7% | |
| Q4 2025 | +2.1% | +9.2% | +4.1% | |
| Q3 2025 | +20.4% | +18.6% | +39.1% | |
| Q2 2025 | +1.8% | -5.1% | +11.1% | |
| Q1 2025 | +8.9% | +11.4% | +10.2% | |
| Q4 2024 | -13.9% | -19.4% | -23.5% | |
| Q3 2024 | -6.8% | -7.5% | -7.7% | |
| Q2 2024 | +6.9% | +1.6% | +15.0% | |
| Q1 2024 | +14.7% | +21.0% | +20.6% | |
| Q4 2023 | +6.2% | +5.5% | +15.1% | |
| Q3 2023 | -3.0% | -2.4% | +8.6% | |
| Q2 2023 | +15.4% | +16.2% | +18.7% | |
| Q1 2023 | -9.8% | -11.3% | -19.5% | |
| Q4 2022 | -9.8% | -5.4% | -16.3% | |
| Q3 2022 | -3.3% | +3.7% | -1.1% | |
| Q2 2022 | +27.1% | +30.5% | +37.6% | |
| Q1 2022 | -2.3% | -8.1% | +11.6% | |
| Q4 2021 | +6.3% | +2.8% | -9.8% | |
| Q3 2021 | -7.0% | -1.7% | -9.6% | |
| Q2 2021 | +8.6% | +10.4% | +4.8% | |
| Q1 2021 | +2.6% | +4.2% | +0.3% | |
| Q4 2020 | -11.8% | -13.2% | -15.8% | |
| Q3 2020 | -1.0% | +4.5% | +11.6% | |
| Q2 2020 | +3.0% | +0.6% | -22.1% | |
| Q1 2020 | +7.7% | +9.0% | +22.5% | |
| Q4 2019 | +1.9% | -0.9% | -31.9% | |
| Q3 2019 | +14.8% | +18.6% | +22.5% | |
| Q2 2019 | +3.3% | -0.6% | -0.7% | |
| Q1 2019 | -0.3% | -4.1% | -43.2% | |
| Q4 2018 | -9.6% | -6.0% | -13.7% | |
| Q3 2018 | +13.1% | +15.6% | +7.8% | |
| Q2 2018 | -7.1% | -2.5% | -4.0% | |
| Q1 2018 | -4.1% | +1.6% | +17.7% | |
| Q4 2017 | -10.7% | -11.2% | -8.0% | |
| Q3 2017 | -18.7% | -16.6% | +8.8% | |
| Q2 2017 | -34.1% | -16.2% | -39.4% | |
| Q1 2017 | +1.7% | +1.3% | -3.6% | |
| Q4 2016 | +8.4% | +9.4% | +6.7% | |
| Q3 2016 | -7.2% | -6.0% | -10.5% | |
| Q2 2016 | +1.2% | -6.2% | -8.8% | |
| Q1 2016 | +5.2% | +1.7% | +10.8% | |
| Q4 2015 | -2.0% | — | — | |
| Q3 2015 | -5.1% | — | — | |
| Q2 2015 | -2.6% | — | — | |
| Q1 2015 | +0.1% | — | — | |
| Q3 2014 | +3.6% | — | — | |
| Q4 2014 | +2.0% | — | — | |
| Q2 2014 | -1.6% | — | — | |
| Q1 2014 | +2.0% | — | — | |
| Q4 2013 | -1.9% | — | — | |
| Q3 2013 | -1.5% | — | — | |
| Q2 2013 | -2.0% | — | — | |
| Q1 2013 | +1.0% | — | — | |
| Q4 2012 | +1.4% | — | — | |
| Q3 2012 | +2.6% | — | — | |
| Q2 2012 | -3.3% | — | — | |
| Q1 2012 | -5.4% | — | — | |
| Q4 2011 | +2.5% | — | — | |
| Q3 2011 | +7.0% | — | — | |
| Q2 2011 | +1.9% | — | — | |
| Q1 2011 | +5.6% | — | — | |
| Q4 2010 | +0.4% | — | — | |
| Q3 2010 | +0.3% | — | — | |
| Q2 2010 | -3.4% | — | — | |
| Q1 2010 | +0.9% | — | — | |
| Q4 2007 | +1.2% | — | — | |
| Q4 2009 | +1.2% | — | — | |
| Q3 2008 | -1.4% | — | — | |
| Q3 2009 | -1.4% | — | — | |
| Q2 2008 | -0.8% | — | — | |
| Q2 2009 | -0.8% | — | — | |
| Q1 2009 | -0.6% | — | — | |
| Q1 2008 | -0.6% | — | — | |
| Q4 2008 | -0.6% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro